JP2021102650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021102650A5 JP2021102650A5 JP2021064764A JP2021064764A JP2021102650A5 JP 2021102650 A5 JP2021102650 A5 JP 2021102650A5 JP 2021064764 A JP2021064764 A JP 2021064764A JP 2021064764 A JP2021064764 A JP 2021064764A JP 2021102650 A5 JP2021102650 A5 JP 2021102650A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- agonist
- administration
- composition according
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022155051A JP2022173426A (ja) | 2015-09-30 | 2022-09-28 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2024204921A JP2025019234A (ja) | 2015-09-30 | 2024-11-25 | メラノコルチン４受容体経路関連障害を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235003P | 2015-09-30 | 2015-09-30 | |
| US62/235,003 | 2015-09-30 | ||
| JP2018517270A JP6940853B2 (ja) | 2015-09-30 | 2016-09-29 | メラノコルチン４受容体経路関連障害を治療する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517270A Division JP6940853B2 (ja) | 2015-09-30 | 2016-09-29 | メラノコルチン４受容体経路関連障害を治療する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155051A Division JP2022173426A (ja) | 2015-09-30 | 2022-09-28 | メラノコルチン４受容体経路関連障害を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021102650A JP2021102650A (ja) | 2021-07-15 |
| JP2021102650A5 true JP2021102650A5 (enExample) | 2021-10-28 |
| JP7752373B2 JP7752373B2 (ja) | 2025-10-10 |
Family
ID=57138146
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517274A Active JP7051106B2 (ja) | 2015-09-30 | 2016-09-29 | メラノコルチン－４受容体経路関連障害の治療方法 |
| JP2018517270A Active JP6940853B2 (ja) | 2015-09-30 | 2016-09-29 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2021041611A Pending JP2021088611A (ja) | 2015-09-30 | 2021-03-15 | メラノコルチン−４受容体経路関連障害の治療方法 |
| JP2021064764A Active JP7752373B2 (ja) | 2015-09-30 | 2021-04-06 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2022155051A Pending JP2022173426A (ja) | 2015-09-30 | 2022-09-28 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2023044399A Pending JP2023078335A (ja) | 2015-09-30 | 2023-03-20 | メラノコルチン－４受容体経路関連障害の治療方法 |
| JP2024204921A Pending JP2025019234A (ja) | 2015-09-30 | 2024-11-25 | メラノコルチン４受容体経路関連障害を治療する方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517274A Active JP7051106B2 (ja) | 2015-09-30 | 2016-09-29 | メラノコルチン－４受容体経路関連障害の治療方法 |
| JP2018517270A Active JP6940853B2 (ja) | 2015-09-30 | 2016-09-29 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2021041611A Pending JP2021088611A (ja) | 2015-09-30 | 2021-03-15 | メラノコルチン−４受容体経路関連障害の治療方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155051A Pending JP2022173426A (ja) | 2015-09-30 | 2022-09-28 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2023044399A Pending JP2023078335A (ja) | 2015-09-30 | 2023-03-20 | メラノコルチン－４受容体経路関連障害の治療方法 |
| JP2024204921A Pending JP2025019234A (ja) | 2015-09-30 | 2024-11-25 | メラノコルチン４受容体経路関連障害を治療する方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US20180215790A1 (enExample) |
| EP (4) | EP3356386B1 (enExample) |
| JP (7) | JP7051106B2 (enExample) |
| KR (1) | KR20180063221A (enExample) |
| CN (2) | CN108431023B (enExample) |
| AU (6) | AU2016330772A1 (enExample) |
| BR (1) | BR112018006674A2 (enExample) |
| CA (2) | CA3000670A1 (enExample) |
| DK (1) | DK3356386T3 (enExample) |
| ES (1) | ES2985734T3 (enExample) |
| FI (1) | FI3356386T3 (enExample) |
| HK (1) | HK1259424A1 (enExample) |
| IL (3) | IL299541A (enExample) |
| MA (2) | MA43040A (enExample) |
| MX (2) | MX2018003983A (enExample) |
| PL (1) | PL3356386T3 (enExample) |
| PT (1) | PT3356386T (enExample) |
| SG (1) | SG10202101510XA (enExample) |
| WO (2) | WO2017059075A1 (enExample) |
| ZA (1) | ZA201802704B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62701B1 (sr) | 2011-12-29 | 2022-01-31 | Rhythm Pharmaceuticals Inc | Postupak lečenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima |
| EP3356386B1 (en) * | 2015-09-30 | 2024-02-14 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor pathway-associated disorders |
| SG11202004373RA (en) * | 2017-11-15 | 2020-06-29 | Rhythm Pharmaceuticals Inc | Sustained release peptide formulations |
| EP3755362B1 (en) | 2018-02-20 | 2025-11-19 | Charité - Universitätsmedizin Berlin | Mc4r agonist efficacy in subjects with mc4r deficiencies and impaired nfat signaling |
| US20210221867A1 (en) | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
| CN108841932B (zh) * | 2018-07-13 | 2021-03-12 | 东北农业大学 | 一种预示和鉴定鸡腹部脂肪量的分子标记方法及应用 |
| US12049670B2 (en) * | 2020-05-04 | 2024-07-30 | Regeneron Pharmaceuticals, Inc. | Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereof |
| MX2023003360A (es) * | 2020-09-24 | 2023-06-23 | Rhythm Pharmaceuticals Inc | Metodos de tratamiento de trastornos asociados a la via del receptor de melanocortina-4. |
| EP4605077A1 (en) | 2022-10-18 | 2025-08-27 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| EP4618952A2 (en) * | 2022-11-18 | 2025-09-24 | Rhythm Pharmaceuticals, Inc. | Methods for treating obesity with an mc4r agonist |
| WO2024155828A1 (en) * | 2023-01-18 | 2024-07-25 | Loma Linda University Health | Uses of aminopyridines in the management of weight and satiety |
| CN118530299B (zh) * | 2023-08-25 | 2025-02-07 | 广州益养生物科技有限公司 | 一种三肽、三肽盐或衍生物及其应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5226895A (en) | 1989-06-05 | 1993-07-13 | Eli Lilly And Company | Multiple dose injection pen |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| AU1860697A (en) | 1995-09-08 | 1997-07-28 | Visionary Medical Products Corporation | Pen-type injector drive mechanism |
| US5688251A (en) | 1995-09-19 | 1997-11-18 | Becton Dickinson And Company | Cartridge loading and priming mechanism for a pen injector |
| US20030144174A1 (en) | 1998-12-09 | 2003-07-31 | Miles B. Brennan | Methods for identifying compounds useful for the regulation of body weight and associated conditions |
| US6603058B1 (en) | 1998-12-09 | 2003-08-05 | Oklahoma Medical Research Foundation | Non-human animal model for obesity and uses thereof |
| US7319107B2 (en) | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| DE10251673A1 (de) | 2001-11-09 | 2003-07-10 | Hoffmann La Roche | Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms |
| WO2004076690A2 (de) | 2003-02-19 | 2004-09-10 | Universit�T Duisburg-Essen | Verwendung einer genveränderung im humanen gnas-gen zur vorhersage von erkrankungsrisiken, krankheitsverläufen und zur vorhersage des ansprechens auf krankheitstherapien |
| GB0304822D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| DE602004012403T2 (de) | 2003-04-29 | 2009-03-19 | Orexigen Therapeutics, Inc., La Jolla | Zusammensetzungen zur beeinflussung des gewichtsverlusts |
| US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| US20070105759A1 (en) | 2003-06-19 | 2007-05-10 | Eli Lilly And Company | Melanocortin receptor 4 (mc4) agonists and their uses |
| US7910101B2 (en) | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| EP3925614A3 (en) | 2005-07-08 | 2022-03-23 | Ipsen Pharma | Melanocortin receptor ligands |
| RU2401841C2 (ru) | 2005-07-08 | 2010-10-20 | Ипсен Фарма С.А.С. | Лиганды рецепторов меланокортинов |
| US8247530B2 (en) | 2005-11-08 | 2012-08-21 | Palatin Technologies, Inc. | N-alkylated cyclic peptide melanocortin agonists |
| US8114844B2 (en) | 2006-03-30 | 2012-02-14 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptidomimetics |
| EP2106406A2 (en) | 2007-01-18 | 2009-10-07 | Novo Nordisk A/S | Novel peptides for use in the treatment of obesity |
| WO2008087187A1 (en) | 2007-01-18 | 2008-07-24 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
| US20100016237A1 (en) | 2007-01-18 | 2010-01-21 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
| JP2010516654A (ja) | 2007-01-18 | 2010-05-20 | ノボ・ノルデイスク・エー／エス | 肥満の治療に使用される新規ペプチド |
| EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| US8563000B2 (en) | 2007-05-25 | 2013-10-22 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| EP2019100A1 (en) | 2007-07-19 | 2009-01-28 | Santhera Pharmaceuticals (Schweiz) AG | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| AR072072A1 (es) | 2008-06-09 | 2010-08-04 | Palatin Technologies Inc | Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669 |
| AU2009257631B2 (en) | 2008-06-09 | 2014-07-24 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
| WO2010015972A1 (en) | 2008-08-06 | 2010-02-11 | Pfizer Limited | Diazepine and diazocane compounds as mc4 agonists |
| JP2012501334A (ja) | 2008-08-29 | 2012-01-19 | トランス テック ファーマ，インコーポレイテッド | 置換アミノチアゾール誘導体、医薬組成物、および使用の方法 |
| US9393369B2 (en) | 2008-09-15 | 2016-07-19 | Medimop Medical Projects Ltd. | Stabilized pen injector |
| EP2168965A1 (en) | 2008-09-25 | 2010-03-31 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists |
| WO2010037081A1 (en) | 2008-09-29 | 2010-04-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific spiro-piperidine compounds |
| FR2937868B1 (fr) | 2008-11-04 | 2010-11-05 | Galderma Res & Dev | Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
| FR2937973B1 (fr) | 2008-11-04 | 2010-11-05 | Galderma Res & Dev | Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
| UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| EP2370104A1 (en) | 2008-11-25 | 2011-10-05 | Novo Nordisk A/S | Peptides for treatment of obesity |
| WO2010065802A2 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds |
| WO2010065801A1 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Amine substituted piperazine melanocortin receptor-specific compounds |
| WO2010065800A1 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Hydrazine substituted piperidine melanocortin receptor-specific compounds |
| WO2010065799A2 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Amine substituted piperidine melanocortin receptor-specific compounds |
| EP2210885A1 (en) | 2009-01-14 | 2010-07-28 | Santhera Pharmaceuticals (Schweiz) AG | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| WO2010096854A1 (en) | 2009-02-27 | 2010-09-02 | Mimetica Pty Ltd | Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors |
| WO2010144341A2 (en) | 2009-06-08 | 2010-12-16 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
| CN105037502A (zh) * | 2009-06-08 | 2015-11-11 | 帕拉丁科技公司 | 黑皮质素受体特异性肽 |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| MX2012001513A (es) | 2009-08-05 | 2012-05-22 | Ipsen Pharma Sas | Uso de melanocortinas para tratar la dislipidemia. |
| EP2473518B1 (en) | 2009-08-31 | 2017-02-22 | Tensive Controls, Inc. | Stabilized melanocortin ligands |
| ES2654147T3 (es) * | 2009-11-16 | 2018-02-12 | Ipsen Pharma S.A.S. | Composiciones farmacéuticas de ligandos del receptor de melanocortina |
| BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
| WO2011104378A1 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides for treatment of obesity |
| RS62701B1 (sr) * | 2011-12-29 | 2022-01-31 | Rhythm Pharmaceuticals Inc | Postupak lečenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima |
| CA2906694A1 (en) | 2013-03-15 | 2014-09-18 | Rhythm Metabolic, Inc. | Peptide compositions |
| EP3778623A1 (en) | 2013-03-15 | 2021-02-17 | Rhythm Pharmaceuticals, Inc. | Pharmaceutical compositions |
| EP3356386B1 (en) * | 2015-09-30 | 2024-02-14 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor pathway-associated disorders |
-
2016
- 2016-09-29 EP EP16782150.3A patent/EP3356386B1/en active Active
- 2016-09-29 FI FIEP16782150.3T patent/FI3356386T3/fi active
- 2016-09-29 MA MA043040A patent/MA43040A/fr unknown
- 2016-09-29 DK DK16782150.3T patent/DK3356386T3/da active
- 2016-09-29 WO PCT/US2016/054455 patent/WO2017059075A1/en not_active Ceased
- 2016-09-29 HK HK19101826.7A patent/HK1259424A1/zh unknown
- 2016-09-29 EP EP21204226.1A patent/EP4029513A1/en active Pending
- 2016-09-29 JP JP2018517274A patent/JP7051106B2/ja active Active
- 2016-09-29 WO PCT/US2016/054457 patent/WO2017059076A1/en not_active Ceased
- 2016-09-29 PL PL16782150.3T patent/PL3356386T3/pl unknown
- 2016-09-29 US US15/764,730 patent/US20180215790A1/en active Pending
- 2016-09-29 US US15/764,725 patent/US10960046B2/en active Active
- 2016-09-29 JP JP2018517270A patent/JP6940853B2/ja active Active
- 2016-09-29 CN CN201680057324.6A patent/CN108431023B/zh active Active
- 2016-09-29 KR KR1020187012330A patent/KR20180063221A/ko active Pending
- 2016-09-29 CA CA3000670A patent/CA3000670A1/en active Pending
- 2016-09-29 SG SG10202101510XA patent/SG10202101510XA/en unknown
- 2016-09-29 CA CA3000673A patent/CA3000673A1/en active Pending
- 2016-09-29 EP EP16782343.4A patent/EP3355905A1/en not_active Withdrawn
- 2016-09-29 MX MX2018003983A patent/MX2018003983A/es unknown
- 2016-09-29 ES ES16782150T patent/ES2985734T3/es active Active
- 2016-09-29 AU AU2016330772A patent/AU2016330772A1/en not_active Abandoned
- 2016-09-29 PT PT167821503T patent/PT3356386T/pt unknown
- 2016-09-29 EP EP24150717.7A patent/EP4360704A3/en active Pending
- 2016-09-29 BR BR112018006674-5A patent/BR112018006674A2/en active Search and Examination
- 2016-09-29 AU AU2016330773A patent/AU2016330773A1/en not_active Abandoned
- 2016-09-29 CN CN201680064771.4A patent/CN108601816A/zh active Pending
- 2016-09-29 MA MA043038A patent/MA43038A/fr unknown
- 2016-09-29 IL IL299541A patent/IL299541A/en unknown
-
2018
- 2018-03-27 IL IL258412A patent/IL258412B2/en unknown
- 2018-03-28 MX MX2023003358A patent/MX2023003358A/es unknown
- 2018-04-23 ZA ZA2018/02704A patent/ZA201802704B/en unknown
-
2021
- 2021-02-09 US US17/171,563 patent/US12263202B2/en active Active
- 2021-03-05 AU AU2021201448A patent/AU2021201448A1/en not_active Abandoned
- 2021-03-15 JP JP2021041611A patent/JP2021088611A/ja active Pending
- 2021-04-06 JP JP2021064764A patent/JP7752373B2/ja active Active
-
2022
- 2022-01-20 IL IL289996A patent/IL289996B2/en unknown
- 2022-04-04 US US17/712,752 patent/US20220226425A1/en active Pending
- 2022-09-28 JP JP2022155051A patent/JP2022173426A/ja active Pending
- 2022-11-29 AU AU2022279420A patent/AU2022279420B2/en active Active
-
2023
- 2023-03-20 JP JP2023044399A patent/JP2023078335A/ja active Pending
- 2023-09-12 AU AU2023229494A patent/AU2023229494A1/en active Pending
-
2024
- 2024-09-25 US US18/895,435 patent/US20250195606A1/en active Pending
- 2024-11-25 JP JP2024204921A patent/JP2025019234A/ja active Pending
- 2024-12-19 AU AU2024278597A patent/AU2024278597A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021102650A5 (enExample) | ||
| JP2018531937A5 (enExample) | ||
| Paran et al. | Octreotide treatment in patients with severe acute pancreatitis | |
| Sartor | Eligard: leuprolide acetate in a novel sustained-release delivery system | |
| RU2401841C2 (ru) | Лиганды рецепторов меланокортинов | |
| CA2614615A1 (en) | Melanocortin receptor ligands | |
| Page | Immunologic effects of opioids in the presence or absence of pain | |
| JP2010090130A5 (enExample) | ||
| US8877203B2 (en) | Composition and method for preventing and treating immune-related disorder | |
| FI3356386T3 (fi) | Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä | |
| US20100221274A1 (en) | Method of administering a thymosin alpha 1 peptide | |
| Germain et al. | Pulsatile gonadotropin-releasing hormone therapy in persistent amenorrheic weight-recovered anorexia nervosa patients | |
| Holstad et al. | A transcriptional inhibitor of TNF-α prevents diabetes induced by multiple low-dose streptozotocin injections in mice | |
| AU2002363248A1 (en) | Method of administering a Thymosin alpha 1 peptide | |
| Ohnishi et al. | Morphine blocks the bradycardia associated with severe hemorrhage in the anesthetized rat | |
| Stewart et al. | The future of somatostatin analogue therapy | |
| CN113956334B (zh) | 一种棕色脂肪细胞分泌肽及其衍生物在肥胖防治中的应用 | |
| CN108697758B (zh) | 用于有效控制急性和/或慢性疼痛的药物及其施用方法 | |
| RU2025100211A (ru) | Способы лечения ожирения агонистом mc4r | |
| JPWO2022067086A5 (enExample) | ||
| CN105435215A (zh) | 重组人钙调磷酸酶b亚基的应用 | |
| RU2022132255A (ru) | Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4 | |
| Kurnatowska et al. | Anti-inflammatory effects of somatostatin analogs on zymosan-induced earlobe inflammation in mice: comparison with dexamethasone and ketoprofen | |
| US11167005B2 (en) | Peptides for treating Sjogren's syndrome | |
| Staykova et al. | Infusion of soluble myelin basic protein protects long term against induction of experimental autoimmune encephalomyelitis |